Home

Mesothelioma

• About Mesothelioma
• Mesothelioma Cause
• Mesothelioma Symptoms
• Mesothelioma Diagnosis
• Mesothelioma Stages

Mesothelioma Treatment

• Treatment Options
• Mesothelioma Surgery
• Mesothelioma Chemotherapy
• Mesothelioma Radiation
• New Approaches
• Palliative Care

Mesothelioma Specialists

• Choosing Your Doctor
• Your Health Care Team
• Cancer Centers

Clinical Trials

• Trial Basics
• Eligibility
• Current Trials

Managing Your Care

• Your Personal Records
• Your Medications
• Your Expenses

Veterans Resources

• Asbestos Disease
• Mesothelioma Detection
• Asbestos Exposure
• Veteran Service Officers

Par Pharmaceuticals licenses Onconase

Par Pharmaceutical Companies Inc. has reached an agreement to acquire exclusive licensing and commercialization rights for the drug Onconase. The drug, discovered by Alfacell Corp., is currently in Phase III testing/development for the treatment of malignant mesothelioma.

Par's Strativa Pharmaceuticals unit will make an initial payment of $5 million to Alfacell with an additional $30 million paid upon approval of the drug by the FDA. Alfacell will retain co-promotional rights and will be entitled to royalty payments and additonal undisclosed incentives.

The drug is made from an extract found in oocytes of the Northen Leopard Frog.

 

 

 

Contact Us

**For a FREE information packet including treatments, clinical trials, and specialists, please complete the form above or call a Mesothelioma Web coordinator at 1-877-367-6376.

News

• Mesothelioma News
• International News
• Pharmaceutical News
• Environmental News
• Medical Journal Articles

Resources

• Leading Cancer Links
• Financial Assistance, Compensation, and Legal Rights
• Disclaimer and Sponsorship Information

If you would like to receive a FREE information packet or have questions about mesothelioma, call us at:

Toll-Free 1-877-367-6376